Back to News
Market Impact: 0.2
Join Anixa Biosciences' Live Investor Webinar: Advancing Innovative CAR-T Therapy for Ovarian Cancer and a First-in-Class Breast Cancer Vaccine
Source: Newswire
Healthcare & BiotechCompany Fundamentals
Anixa says it is advancing two clinical-stage oncology programs: a CAR-T program and a breast cancer vaccine. The company reports that the vaccine completed a Phase 1 trial, with Phase 2 development planned; management is set to discuss clinical progress and upcoming milestones.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
ANIX0.35
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Wells Fargo CFO on Earnings, Deals, Consumer Strength
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AllMind Fixed Income Compass for October 2025: Navigating Policy Divergence and Political Risk
- AI Equity Research Tools for RIAs and Wealth Managers